drugset / Trial / NCT02823106
Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a phase 1, blinded-outcome, randomized, placebo controlled study to investigate the safety and feasibility of super-selective intra-arterial administration of verapamil and citicoline immediately following successful endovascular thrombectomy as a potential neuroprotective synergistic therapeutic strategy in emergent large vessel occlusion stroke. This trial represents the first time that citicoline will be evaluated in human subjects as a superselectively administered neuroprotective agent administered in an acute time frame as an adjunct to intra-arterial thrombectomy. Furthermore, it will represent the first trial to evaluate combinational therapy for acute stroke neuroprotection.
Timeline
- Start
- 2016-08
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Citicoline | Other / unclassified | 1000 mg | Other |
| Subject | Verapamil | Other / unclassified | 10 mg | Other |